ATRC Stock: Price, Earnings History and SEC Filings
AtriCure, Inc. (ATRC) last traded at $61.25, down 1.97% on the latest session and up 9.0% over the past month. In its most recent reported quarter (Jun 2026) earnings per share were $0.18 against an analyst estimate of $0.03, a beat of 500.0%.
Price data from Yahoo Finance, as of Oct 30, 2026. May be delayed.
ATRC earnings history
| Quarter | Reported | EPS | Estimate | Surprise |
|---|---|---|---|---|
| Jun 2026 | Jul 23, 2026 | $0.18 | $0.03 | +500.00% |
| Mar 2026 | May 5, 2026 | $0.00 | $-0.07 | +100.00% |
| Dec 2025 | Feb 17, 2026 | $0.06 | $-0.02 | +400.00% |
| Sep 2025 | Oct 29, 2025 | $-0.01 | $-0.11 | +90.91% |
ATRC beat the analyst EPS estimate in 4 of its last 4 reported quarters. Source: Nasdaq.
How ATRC reacts to earnings
Across its last 8 earnings releases, ATRC moved 7.1% on average the next session, in either direction. It rose after 2 of 8 reports.
| Report date | Released | Next-session move |
|---|---|---|
| 2026-07-23 | After close | +6.18% |
| 2026-05-05 | After close | -4.70% |
| 2026-02-17 | After close | -2.15% |
| 2026-01-12 | Before open | -9.21% |
| 2025-10-29 | After close | -3.81% |
| 2025-07-29 | After close | +10.72% |
| 2025-04-29 | After close | -13.68% |
| 2025-02-12 | After close | -6.54% |
Based on the dates of earnings-release 8-K filings (SEC EDGAR) and daily closing prices (Yahoo Finance). Past reactions do not predict future ones.
ATRC financial history
| Fiscal year | Revenue | Net income | Free cash flow | Net margin | Diluted EPS |
|---|---|---|---|---|---|
| 2025 | $535M | -$11M | $48M | -2.1% | $-0.24 |
| 2024 | $465M | -$45M | $745000 | -9.6% | $-0.95 |
| 2023 | $399M | -$30M | -$8M | -7.6% | $-0.66 |
| 2022 | $330M | -$46M | -$39M | -14.1% | $-1.02 |
| 2021 | $274M | $50M | -$24M | 18.3% | $1.09 |
| 2020 | $207M | -$48M | -$25M | -23.3% | $-1.14 |
| 2019 | $231M | -$35M | -$28M | -15.2% | $-0.94 |
| 2018 | $202M | -$21M | -$10M | -10.5% | – |
Source: annual figures from 10-K filings on SEC EDGAR. The year shown is the calendar year the fiscal year ended. Free cash flow is operating cash flow minus capital spending.
Latest SEC filings for ATRC
- 10-Q · Jul 27, 2026
- 8-K · Jul 23, 2026Results of operations, Financial statements and exhibits
- 8-K · May 19, 2026Officer or director change, Shareholder vote, Financial statements and exhibits
- 10-Q · May 6, 2026
- 8-K · May 5, 2026Results of operations, Financial statements and exhibits
- DEF 14A · Apr 6, 2026
- 10-K · Feb 19, 2026
- 8-K · Feb 17, 2026Results of operations, Financial statements and exhibits
- 8-K · Jan 12, 2026Material agreement, Results of operations, New financial obligation
- 10-Q · Oct 30, 2025
Insider filing activity
ATRC insiders filed 7 Form 4 reports in the last 90 days. A Form 4 is how directors and executives disclose purchases, sales and grants of company stock. See the individual filings on SEC EDGAR. Many Form 4 filings are routine, such as scheduled sales or option exercises, so check each filing before drawing a conclusion.
Source: SEC EDGAR.
ATRC news
- AtriCure to Participate at Upcoming Investor ConferencesOct 26, 2026 · finance.yahoo.com
About AtriCure, Inc.
AtriCure, Inc. (ATRC) is a US-listed public company on Nasdaq. The SEC classifies its business as Surgical & Medical Instruments & Apparatus. It is incorporated in DE. Its fiscal year ends in December.